Search

#Biopharma

DIE WELT 4w

Die Schließung mehrerer Produktionsstandorte von Biontech, die auf Überkapazitäten und Kosteneinsparungen zurückzuführen ist, wurde als schmerzhafter Einschnitt für die Biotechnologiebranche und die betroffenen Regionen bezeichnet, während die Gründer von Curevac dem Management von Biontech Täuschung vorwerfen und vermuten, dass die Schließungen mit Patentstreitigkeiten zusammenhängen könnten. #Biotechnology #Biopharma #JobLosses

Rheinland-Pfalz bleibt an der Seite von Biontech - WELT

T-online.de 4w

Biontech plant die Schließung mehrerer Produktionsstandorte, darunter in Idar-Oberstein, Marburg und Singapur, aufgrund von Überkapazitäten und Kosteneinsparungen, wodurch bis zu 1.860 Stellen betroffen sein könnten, während das Unternehmen 2029 jährliche Einsparungen von bis zu 500 Millionen Euro anstrebt, um in die Krebsforschung zu investieren. #Biopharma #Biontech #COVID19

Biontech schließt Standorte: Fast 2.000 Jobs bedroht

Seeking Alpha Jan 20

#HealthcareInnovation #Biopharmaceuticals #GlobalMarkets

Hello, Goodbye: Europe Loses Ground As China Becomes Powerhouse Of Innovation

Seeking Alpha Jan 20

#HealthcareInnovation #Biopharmaceuticals #GlobalMarkets

Hello, Goodbye: Europe Loses Ground As China Becomes Powerhouse Of Innovation

Benzinga Jan 5

#Biopharmaceuticals #Neuroscience #HealthcareInnovation

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Xenon Pharmaceuticals (NASDAQ:XENE)

Benzinga Jan 5

#Biopharmaceuticals #Neuroscience #HealthcareInnovation

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Xenon Pharmaceuticals (NASDAQ:XENE)

Benzinga Jan 5

#GeneticMedicine #Biopharmaceuticals #Leadership

ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors

Benzinga Jan 5

#GeneticMedicine #Biopharmaceuticals #Leadership

ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors

Benzinga Jan 5

#Pelthos #Xeglyze #Biopharmaceuticals

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)

Benzinga Jan 5

#Pelthos #Xeglyze #Biopharmaceuticals

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)

Benzinga Jan 5

#Pelthos #Xeglyze #Biopharmaceuticals

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)

Benzinga Jan 5

#Biopharmaceuticals #GeneticDiseases #HealthcareConference

BridgeBio to Participate in the J.P. Morgan Healthcare Conference - BridgeBio Pharma (NASDAQ:BBIO)

Benzinga Jan 5

#Biopharmaceuticals #GeneticDiseases #HealthcareConference

BridgeBio to Participate in the J.P. Morgan Healthcare Conference - BridgeBio Pharma (NASDAQ:BBIO)

Benzinga Jan 5

#Biopharmaceuticals #LiverDisease #FDAApproval

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)

Benzinga Jan 5

#Biopharmaceuticals #LiverDisease #FDAApproval

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)

Benzinga Jan 5

#Biopharma #Neuroscience #ClinicalTrials

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)

Benzinga Jan 5

#Biopharma #Neuroscience #ClinicalTrials

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)

NASDAQ Stock Market Jan 5

#biopharmaceuticals #cancerresearch #clinicaltrials

HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer

NASDAQ Stock Market Jan 5

#biopharmaceuticals #cancerresearch #clinicaltrials

HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer